Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Weight Loss: The Data At this time, there arent any published head-to-head obesity trials directly comparing oral semaglutide to orforglipron, says Maria Teresa Anton, MD, a board-certified internal medicine physician who specializes in endocrinology, diabetes, and metabolism with Pritikin Longevity Center in Miami
FDA Approves Oral Semaglutide as the First Oral GLP-1 Pill for Weight Loss At Dr
Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study
doi: 10.3389/fendo.2014.00110 53 BassilFFernagutPOBezardEMeissnerWG
These enforcement efforts align with increased regulatory oversight
